or nonfatal stroke and a 42% decrease in the overall incidence of cardiovascular events.84,85
In the Heart Protection Study, which included 20,536
patients, 3280 had a history of nondisabling ischemic
stroke or TIAs and were randomized to 40 mg of simvastatin or placebo. There was a 25% (95% CI, 15-34) proportional reduction